Background: JC-001 is a Chinese medicine that can modulate the immunity in Hepa 1-6 tumor-bearing mice, and we\nquestioned whether JC-001 can serve as efficient adjuvant chemotherapy. We aimed to identify a novel approach for\nenhancing cis-diamminedichloroplatinum (II) (CDDP)-based chemotherapy by immunomodulation.\nMethods: The anti-tumor activity in vitro was determined based on foci formation and a 3-(4,5-dimethylthiazol-2-yl)-\n2,5-diphenyltetrazolium bromide (MTT) assay. A LLC1 tumor xenograft model was used to analyze the activity of tumor\nrejection in vivo. The tumors were analyzed through hematoxylin and eosin (H&E) staining, immunohistochemistry\n(IHC) staining and cytokine arrays.\nResults: JC-001 suppressed foci formation and reduced the viability of Lewis lung carcinoma (LLC1) cells in vitro. JC-001\nsuppressed LLC1 tumor growth in immunodeficient BALB/c nude mice and in immunocompetent C57BL/6 mice to an\neven greater extent. Furthermore, JC-001 up-regulated interferon-�³ expression in the tumor microenvironment, enhanced\nthe Th1 response in tumor-bearing mice, and increased the chemosensitivity of LLC1 tumors to CDDP chemotherapy.\nThe results of our study suggest that JC-001 is associated with low cytotoxicity and can significantly suppress tumor\ngrowth by enhancing the Th1 response.\nConclusion: JC-001 is a Chinese medicine with potential clinical applications in CDDP-based chemotherapeutic regimens.
Loading....